219 related articles for article (PubMed ID: 15059894)
1. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.
Hippo Y; Watanabe K; Watanabe A; Midorikawa Y; Yamamoto S; Ihara S; Tokita S; Iwanari H; Ito Y; Nakano K; Nezu J; Tsunoda H; Yoshino T; Ohizumi I; Tsuchiya M; Ohnishi S; Makuuchi M; Hamakubo T; Kodama T; Aburatani H
Cancer Res; 2004 Apr; 64(7):2418-23. PubMed ID: 15059894
[TBL] [Abstract][Full Text] [Related]
2. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma.
Chen M; Li G; Yan J; Lu X; Cui J; Ni Z; Cheng W; Qian G; Zhang J; Tu H
Clin Chim Acta; 2013 Aug; 423():105-11. PubMed ID: 23643963
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Nakatsura T; Yoshitake Y; Senju S; Monji M; Komori H; Motomura Y; Hosaka S; Beppu T; Ishiko T; Kamohara H; Ashihara H; Katagiri T; Furukawa Y; Fujiyama S; Ogawa M; Nakamura Y; Nishimura Y
Biochem Biophys Res Commun; 2003 Jun; 306(1):16-25. PubMed ID: 12788060
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
6. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma.
Nakatsura T; Nishimura Y
BioDrugs; 2005; 19(2):71-7. PubMed ID: 15807627
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
11. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma.
Yu JP; Xu XG; Ma RJ; Qin SN; Wang CR; Wang XB; Li M; Li MS; Ma Q; Xu WW
J Clin Lab Anal; 2015 Mar; 29(2):85-93. PubMed ID: 24687454
[TBL] [Abstract][Full Text] [Related]
12. The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma.
Jing JS; Ye W; Jiang YK; Ma J; Zhu MQ; Ma JM; Zhou H; Yu LQ; Yang YF; Wang SC
Clin Lab; 2017 Nov; 63(11):1903-1909. PubMed ID: 29226636
[TBL] [Abstract][Full Text] [Related]
13. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?
Abdelgawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
Asian Pac J Cancer Prev; 2013; 14(12):7345-9. PubMed ID: 24460300
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.
Ozkan H; Erdal H; Koçak E; Tutkak H; Karaeren Z; Yakut M; Köklü S
J Clin Lab Anal; 2011; 25(5):350-3. PubMed ID: 21919070
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.
Hagag NA; Ali YBM; Elsharawy AA; Talaat RM
J Gastrointest Cancer; 2020 Mar; 51(1):234-241. PubMed ID: 31028536
[TBL] [Abstract][Full Text] [Related]
16. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
Zittermann SI; Capurro MI; Shi W; Filmus J
Int J Cancer; 2010 Mar; 126(6):1291-301. PubMed ID: 19816934
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma.
Lee HJ; Yeon JE; Suh SJ; Lee SJ; Yoon EL; Kang K; Yoo YJ; Kim JH; Seo YS; Yim HJ; Byun KS
Gut Liver; 2014 Mar; 8(2):177-85. PubMed ID: 24672660
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
19. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy.
Haruyama Y; Yorita K; Yamaguchi T; Kitajima S; Amano J; Ohtomo T; Ohno A; Kondo K; Kataoka H
Int J Cancer; 2015 Oct; 137(7):1643-51. PubMed ID: 25784484
[TBL] [Abstract][Full Text] [Related]
20. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians.
Gomaa SH; Abaza MM; Elattar HA; Amin GA; Elshahawy DM
Arab J Gastroenterol; 2020 Dec; 21(4):224-232. PubMed ID: 32891543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
